A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens

Trial Profile

A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors National OncoVenture
  • Most Recent Events

    • 09 Dec 2017 Results of exploratory biomarker analysis presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 29 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top